Abstracts tagged "Biologic agents"

Abstract Number: 425 • 2017 ACR/ARHP Annual Meeting
Efficacy of Monotherapy of the Biologic Dmards in Patients with Rheumatoid Arthritis: Real Life Data from the Hong Kong Biologics Registry
Chi Chiu Mok, Ting Hung Wan and Lai Shan Fong, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To report the prevalence and efficacy of biologic DMARD (bDMARD) monotherapy in real life treatment of rheumatoid arthritis (RA). Methods: RA patients registered in…
Abstract Number: 1052 • 2017 ACR/ARHP Annual Meeting
Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor
Aliza Matusevich¹, Maria Suarez-Almazor¹, Scott B. Cantor² and Maria A. Lopez-Olivo¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Results from cost-effectiveness analysis (CEAs) comparing treatment options for patients with rheumatoid arthritis (RA) who have an inadequate response to an initial tumor necrosis…
Abstract Number: 1534 • 2017 ACR/ARHP Annual Meeting
Comparison of Long Term Anti-Tnf Survival in Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis; Data from Turkbio Registry
Gercek Can¹, Ediz Dalkılıc², Yavuz Pehlivan², Soner Senel³, Servet Akar⁴, Dilek Solmaz⁵, Suleyman Serdar Koca⁶, Nevsun İnanc⁷, Pamir Atagunduz⁷, Ayten Yazıcı⁸, Ayse Cefle⁸, Berna Goker⁹, Berrin Zengin¹, Sadettin Uslu¹⁰, Nurullah Akkoc¹¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Rheumatology, Uludag University Faculty of Medicine Rheumatology, bursa, Turkey, ³Rheumatology, Erciyes University Faculty of Medicine Rheumatology, kayseri, Turkey, ⁴Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁵Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, izmir, Turkey, ⁶Rheumatology, Fırat University Faculty of Medicine, elazıg, Turkey, ⁷Rheumatology, Marmara University Faculty of Medicine Rheumatology, istanbul, Turkey, ⁸Rheumatology, Kocaeli University Faculty of Medicine Rheumatology, kocaeli, Turkey, ⁹Rheumatology, Gazi Universty of Fakulty of Medicine, ankara, Turkey, ¹⁰Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ¹¹Rheumatology, Private Practice, Rheumatology, İzmir, Turkey
Background/Purpose: Limited data are available on anti-TNF survival in non-radiographic axial spondyloarthritis (nr-axSpA) patients and their long-term survival in ankylosing spondylitis (AS). The aim of…
Abstract Number: 2382 • 2017 ACR/ARHP Annual Meeting
Reliability of the Biochemical Bone Markers CTX and P1NP during a TNF-Inhibitor Treatment Cycle in Patients with Rheumatoid Arthritis
Kim Holmsted¹, Niklas Rye Jørgensen² and Ole Rintek Madsen¹, ¹Center for Rheumatology and Spine Diseases & The DANBIO Registry, Copenhagen University Hospital Rigshospitalet Gentofte Glostrup, Copenhagen, Denmark, ²Dept. of Clinical Biochemistry, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of developing osteoporosis. Dual Energy X-ray Absorptiometry (DXA) with assessment of BMD is used for…
Abstract Number: 426 • 2017 ACR/ARHP Annual Meeting
Serum Levels of the Anti-TNF Biologics Correlate with Clinical Efficacy in Patients with Inflammatory Arthritis
Chi Chiu Mok¹, Lai Shan Fong¹, Ling Yin Ho² and Chi Hung To³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ³Medicine, Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the correlation between levels of the anti-TNF biologics and clinical efficacy in patients with inflammatory arthritis Methods: Adult patients who fulfilled the…
Abstract Number: 1058 • 2017 ACR/ARHP Annual Meeting
Variation in DMARD Therapy Following Methotrexate Failure for Newly-Identified Rheumatoid Arthritis in a National Veterans Health Administration Cohort
John McDougall Jr.^1,2, Cynthia Brandt^3,4, Melissa Skanderson³, Joseph Goulet³ and Liana Fraenkel⁵, ¹National Clinican Scholars Program, Yale School of Medicine, New Haven, CT, ²Dep't. of Rheumatology, Yale School of Medicine, New Haven, CT, ³Veterans Affairs Connecticut Healthcare System, West Haven, CT, ⁴Emergency Medicine, Yale School of Medicine, New Haven, CT, ⁵Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT
Background/Purpose: Absent contraindications to conventional DMARD (cDMARD) use, the Veterans Administration (VA) requires a 3-month trial of 2 cDMARDs prior to the use of biologic…
Abstract Number: 1539 • 2017 ACR/ARHP Annual Meeting
High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study
Alan J. Kivitz¹, Helena Marzo-Ortega², Clarence Legerton³, Joachim Sieper⁴, Ricardo Blanco⁵, Martin Cohen⁶, Evie Maria Delicha⁷, Susanne Rohrer⁷ and Hanno Richards⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²NIHR LBRC, LTHT and LIRMM, UoL, Leeds, United Kingdom, ³Low Country Rheumatology, Articularis Healthcare, Charleston, SC, ⁴University Clinic Benjamin Franklin, Berlin, Germany, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶McGill University, Montreal, QC, Canada, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab provided sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) over 2 years in the MEASURE 2 study (NCT01649375).1,2 Here we…
Abstract Number: 2386 • 2017 ACR/ARHP Annual Meeting
The Risk Factors of Newly Developing/Worsening Pulmonary Abnormalities in Rheumatoid Arthritis
Ayae Tanaka¹, Kazuhiro Kurasawa¹, Yuta Takamura¹, Tomoyuki Miyao¹, Ryutaro Yamazaki², Satoko Arai¹, Takayoshi Owada¹, Reika Maezawa¹ and Masafumi Arima¹, ¹Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan, ²Rheumatology, Dokkyo Medical University, Mibu, tochigi, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that affects various organs including the lung. The pulmonary involvement is critical for prognosis of the…
Abstract Number: 471 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?
Adeeba Al-Herz¹, Aqeel Ghanem², Khulood Saleh³, Adel Al-Awadhi⁴, Waleed Al-Kandari³, Eman Hasan⁵, Mohammad Hussain⁵, Ibrahim Nahar², Fatemah Abutiban⁶, Ahmad Alenizi⁶, Yaser Ali², Ali Aldei¹, Hebah Alhajeri², Sawsan Hayat², Ahmad Khadrawy³, Ammad Fazal³, Khaled Mokaddem¹, Agaz Zaman², Ghada Mazloum², Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁶ and Ahmed Al-Saber⁷, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ³Rheumatology, Farwania Hospital, Farwania, Kuwait, ⁴Faculty of Medicine, Kuwait, Kuwait, ⁵Al-Amiri Hospital, Kuwait city, Kuwait, ⁶Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁷Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Patients with rheumatoid arthritis (RA) may fail to respond to biologic therapy. We study patients who are resistant to different classes of biologic agents…
Abstract Number: 1158 • 2017 ACR/ARHP Annual Meeting
Treatment of Non-Infectious Uveitis: A Comparative Long-Term Study between Biologic Therapy with Adalimumab and Two Conventional Disease-Modifying Antirheumatic Drugs
Esteban Rubio Romero¹, Roberto Aguilar Galán², Raúl Menor Almagro¹, Alejandro Muñoz¹ and Juan Povedano¹, ¹Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ²Ophthalmology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Background/Purpose: Uveitis are inflammatory processes of the vascular layer of the eye, the uvea, which is divided into iris (anterior uvea), ciliary body (intermediate) and…
Abstract Number: 1541 • 2017 ACR/ARHP Annual Meeting
First Line Biological Treatment in Ankylosing Spondylitis, Prescription Rates, Baseline Demographics and Disease Activity. a Collaboration between Biological Registers in the Five Nordic Counties
Bente Glintborg¹, Ulf Lindström², Kalle Aaltonen³, Eirik K Kristianslund⁴, Björn Gudbjornsson⁵, Katerina Chatzidionysiou², Johan Askling⁶, Dan Nordström⁷, Merete Lund Hetland⁸, Daniela Di Giuseppe⁹, Lene Dreyer¹⁰, Tanja Schjødt Jørgensen¹¹, Lars Erik Kristensen¹⁰, Kari Eklund³, Gerdur Grondal¹², Sofia Ernestam², Jaana Joensuu³, Tore K Kvien¹³, Elisabeth Lie¹³, Karen M Fagerli¹³, Arni Jon Geirsson¹², Helgi Jonsson¹² and Lennart TH Jacobsson¹⁴, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²On behalf of the SRQ/ARTIS registry, Stockholm, Sweden, ³On behalf of the ROB-FIN registry, Helsinki, Finland, ⁴Dept. of Rheumatology, On behalf of the NOR-DMARD registry, Oslo, Norway, ⁵ICEBIO, Reykjavik, Iceland, Reykjavik, Iceland, ⁶Unit of Clinical Epidemiology, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁷ROB-FIN, Helsinki, Finland, Helsinki, Finland, ⁸The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, ⁹Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁰On behalf of the DANBIO registry, Copenhagen, Denmark, ¹¹On behalf of the DANBIO registry, Copenhagen F, Denmark, ¹²On behalf of the ICEBIO registry, Reykjavik, Iceland, ¹³On behalf of the NOR-DMARD registry, Oslo, Norway, ¹⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Large-scale observational cohorts identified in national biological registries may be used to study effectiveness of biological disease modifying drugs (bDMARDs) in ankylosing spondylitis (AS).…
Abstract Number: 2409 • 2017 ACR/ARHP Annual Meeting
Older Age and Male Gender Are Independent Predictors of Quantiferon Positivity Among Adult Rheumatic Patients in a Tertiary Care Center from a BCG Vaccinated Country: Hur-BIO Single Center Real Life Results
Emrah Seyhoglu¹, Oguz Abdullah Uyaroglu¹, Abdulsamet Erden², Levent Kilic², Berkan Armagan², Alper Sari², Omer Karadag², Sule Apras Bilgen², Ali Akdogan², Ihsan Ertenli², Umut Kalyoncu² and Sedat Kiraz², ¹Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: TNF-α inhibitors increase the risk of emergence of active tuberculosis (TB). Screening rheumatic patients for latent TB is a necessity before initiation of biological…
Abstract Number: 475 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patient Characteristics Also Predict Response to Therapy with Biologic Agents: Results from the Corrona Certain Study
Dimitrios A. Pappas¹, James Murray², Carol J. Etzel¹, David R Nelson², Bernice Gershenson³, Katherine C. Saunders¹, Sabrina Rebello¹ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²Eli Lilly and Company, Indianapolis, IN, ³University of Massachusetts Medical School, Worcester, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Response to biologic agents approved for RA may be associated with patient reported factors that are not related to disease and usually not included…
Abstract Number: 1425 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Patients with Rheumatoid Arthritis Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Philip J Mease¹, Neil Accortt², Mei Liu³, Sabrina Rebello³, Mahdi Gharaibeh² and David Collier², ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Amgen Inc., Thousand Oaks, CA, ³Corrona, LLC, Southborough, MA
Background/Purpose: Many treatment options are currently available to patients with rheumatoid arthritis (RA), including tumor necrosis factor inhibitors (TNFi’s). While combination therapy of TNFi’s or…
Abstract Number: 1542 • 2017 ACR/ARHP Annual Meeting
Inequity in Biologic DMARD Prescription for Spa across the Globe: Results from the Multi-Centre, Cross-Sectional, ASAS Comospa Study
Elena Nikiphorou¹, Désirée van der Heijde², Sam Norton³, Robert B.M. Landewé⁴, Anna Moltó⁵, Maxime Dougados⁶, Filip van Den Bosch⁷ and Sofia Ramiro⁸, ¹LUMC, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Academic Rheumatology, King´s College London, London, United Kingdom, ⁴Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵Paris Descartes University, Paris, France, ⁶Paris-Descartes University,, Paris, France, ⁷Rheumatology, Ghent University Hospital, Gent, Belgium, ⁸Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands
Background/Purpose: The value of biologic DMARDs (bDMARDs) in SpA is well recognized but global access to these treatments can be limited due to high cost…

« Previous Page
1
…
5
6
7
8
9
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].